COVID-19对2型糖尿病质量管理影响的多中心研究

IF 0.7 4区 医学 Q4 MEDICAL LABORATORY TECHNOLOGY
Antonio Leon-Justel, Patricia Fernandez-Riejos, Sandra Fuentes, Salomon Martin, Maria J Pareja-Mejia, Maria A Martinez-Brocca, Inmaculada Dominguez, Joaquin Bobillo, Alfonso Soto-Moreno, Maria V Cozar-Leon, Luis M Alvarez-Aragon, Maria E Roldan, Eduardo Mayoral, Juan M Guerrero
{"title":"COVID-19对2型糖尿病质量管理影响的多中心研究","authors":"Antonio Leon-Justel, Patricia Fernandez-Riejos, Sandra Fuentes, Salomon Martin, Maria J Pareja-Mejia, Maria A Martinez-Brocca, Inmaculada Dominguez, Joaquin Bobillo, Alfonso Soto-Moreno, Maria V Cozar-Leon, Luis M Alvarez-Aragon, Maria E Roldan, Eduardo Mayoral, Juan M Guerrero","doi":"10.7754/Clin.Lab.2023.221129","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Epidemics and pandemics have been shown to have widespread effects on health systems. Diabetes is a condition of particular risk during national emergencies such as the COVID-19 pandemic. The aim of this study is to determine the influence of COVID-19 in the patient's diabetes quality management.</p><p><strong>Methods: </strong>We conducted a retrospective multicenter cohort study. Data from type 2 diabetes patients living in Sevilla were included into the study. The study was divided into two observation periods, before and during COVID-19. Metabolic status was assessed using the levels of hemoglobin A1c (A1C) measured during the pre- and CO-VID-19 period. The time interval between sequential A1C tests were also measured. We as well identified the loca-tions where the burden of diabetes quality management is clustered and their relation with demographic and economic factors.</p><p><strong>Results: </strong>We included a total of 106,336 patients from four different hospitals. A significant number patients have worsened their quality management during COVID-19. During the first year of the pandemic, 72,235 patients did not have any hemoglobin A1c (A1C) control. By the time of data extraction, the time between A1C controls was significantly increased by 309 days (from 211 to 520). In addition, 34,001 patients who had A1C control during the COVID-19 period did not reveal a deterioration of their metabolic status. They showed a small but significant metabolic improvement indicated by reduced A1C levels from 52 mmol/mol to 51 mmol/mol. Just like the other group, these patients showed a significant increase of 29 days (from 195 to 224) between A1C controls. COVID-19 increased the substantial clustering for diabetes quality management in specific locations, mostly along the rural southeastern area of Sevilla and these variations were associated with economic and socio-demographic variants.</p><p><strong>Conclusions: </strong>Our study highlighted the great impact of the COVID-19 in diabetes quality management exacerbating the previous inequities and disparities. Our results highlight the need for urgent patient intervention in the areas with high burdens of poorer quality management.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 1","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multicenter Study of the Impact of COVID-19 in Type 2 Diabetes Quality Management.\",\"authors\":\"Antonio Leon-Justel, Patricia Fernandez-Riejos, Sandra Fuentes, Salomon Martin, Maria J Pareja-Mejia, Maria A Martinez-Brocca, Inmaculada Dominguez, Joaquin Bobillo, Alfonso Soto-Moreno, Maria V Cozar-Leon, Luis M Alvarez-Aragon, Maria E Roldan, Eduardo Mayoral, Juan M Guerrero\",\"doi\":\"10.7754/Clin.Lab.2023.221129\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Epidemics and pandemics have been shown to have widespread effects on health systems. Diabetes is a condition of particular risk during national emergencies such as the COVID-19 pandemic. The aim of this study is to determine the influence of COVID-19 in the patient's diabetes quality management.</p><p><strong>Methods: </strong>We conducted a retrospective multicenter cohort study. Data from type 2 diabetes patients living in Sevilla were included into the study. The study was divided into two observation periods, before and during COVID-19. Metabolic status was assessed using the levels of hemoglobin A1c (A1C) measured during the pre- and CO-VID-19 period. The time interval between sequential A1C tests were also measured. We as well identified the loca-tions where the burden of diabetes quality management is clustered and their relation with demographic and economic factors.</p><p><strong>Results: </strong>We included a total of 106,336 patients from four different hospitals. A significant number patients have worsened their quality management during COVID-19. During the first year of the pandemic, 72,235 patients did not have any hemoglobin A1c (A1C) control. By the time of data extraction, the time between A1C controls was significantly increased by 309 days (from 211 to 520). In addition, 34,001 patients who had A1C control during the COVID-19 period did not reveal a deterioration of their metabolic status. They showed a small but significant metabolic improvement indicated by reduced A1C levels from 52 mmol/mol to 51 mmol/mol. Just like the other group, these patients showed a significant increase of 29 days (from 195 to 224) between A1C controls. COVID-19 increased the substantial clustering for diabetes quality management in specific locations, mostly along the rural southeastern area of Sevilla and these variations were associated with economic and socio-demographic variants.</p><p><strong>Conclusions: </strong>Our study highlighted the great impact of the COVID-19 in diabetes quality management exacerbating the previous inequities and disparities. Our results highlight the need for urgent patient intervention in the areas with high burdens of poorer quality management.</p>\",\"PeriodicalId\":10384,\"journal\":{\"name\":\"Clinical laboratory\",\"volume\":\"71 1\",\"pages\":\"\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical laboratory\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.7754/Clin.Lab.2023.221129\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2023.221129","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:流行病和大流行已被证明对卫生系统具有广泛影响。在COVID-19大流行等国家紧急情况期间,糖尿病是一种特别危险的疾病。本研究旨在确定COVID-19对患者糖尿病质量管理的影响。方法:我们进行了一项回顾性多中心队列研究。来自居住在塞维利亚的2型糖尿病患者的数据被纳入研究。该研究分为两个观察期,即COVID-19之前和期间。使用在covid -19前和covid -19期间测量的血红蛋白A1c (A1c)水平评估代谢状态。连续A1C检测之间的时间间隔也被测量。我们还确定了糖尿病质量管理负担集中的地区及其与人口和经济因素的关系。结果:我们共纳入了来自四家不同医院的106,336名患者。在新冠肺炎期间,相当一部分患者的质量管理恶化。在大流行的第一年,72235名患者没有任何糖化血红蛋白(A1c)控制。到数据提取时,A1C对照之间的时间明显增加了309天(从211天增加到520天)。此外,34,001名在COVID-19期间A1C控制的患者没有显示出代谢状况的恶化。他们的糖化血红蛋白水平从52 mmol/mol降至51 mmol/mol,显示出微小但显著的代谢改善。与另一组一样,这些患者的A1C水平与对照组相比显著增加了29天(从195天增加到224天)。COVID-19增加了特定地区(主要是塞维利亚东南部农村地区)糖尿病质量管理的大量聚集性,这些差异与经济和社会人口变异有关。结论:我们的研究强调了COVID-19对糖尿病质量管理的巨大影响,加剧了之前的不公平和差距。我们的研究结果强调,在质量管理负担较差的地区,迫切需要患者干预。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Multicenter Study of the Impact of COVID-19 in Type 2 Diabetes Quality Management.

Background: Epidemics and pandemics have been shown to have widespread effects on health systems. Diabetes is a condition of particular risk during national emergencies such as the COVID-19 pandemic. The aim of this study is to determine the influence of COVID-19 in the patient's diabetes quality management.

Methods: We conducted a retrospective multicenter cohort study. Data from type 2 diabetes patients living in Sevilla were included into the study. The study was divided into two observation periods, before and during COVID-19. Metabolic status was assessed using the levels of hemoglobin A1c (A1C) measured during the pre- and CO-VID-19 period. The time interval between sequential A1C tests were also measured. We as well identified the loca-tions where the burden of diabetes quality management is clustered and their relation with demographic and economic factors.

Results: We included a total of 106,336 patients from four different hospitals. A significant number patients have worsened their quality management during COVID-19. During the first year of the pandemic, 72,235 patients did not have any hemoglobin A1c (A1C) control. By the time of data extraction, the time between A1C controls was significantly increased by 309 days (from 211 to 520). In addition, 34,001 patients who had A1C control during the COVID-19 period did not reveal a deterioration of their metabolic status. They showed a small but significant metabolic improvement indicated by reduced A1C levels from 52 mmol/mol to 51 mmol/mol. Just like the other group, these patients showed a significant increase of 29 days (from 195 to 224) between A1C controls. COVID-19 increased the substantial clustering for diabetes quality management in specific locations, mostly along the rural southeastern area of Sevilla and these variations were associated with economic and socio-demographic variants.

Conclusions: Our study highlighted the great impact of the COVID-19 in diabetes quality management exacerbating the previous inequities and disparities. Our results highlight the need for urgent patient intervention in the areas with high burdens of poorer quality management.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical laboratory
Clinical laboratory 医学-医学实验技术
CiteScore
1.50
自引率
0.00%
发文量
494
审稿时长
3 months
期刊介绍: Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信